Alzheimer's disease drug development pipeline: 2017
Cleveland Clinic · University of Nevada, Las Vegas · +6 more institutions
Indexed incrossrefdoajpubmed
Abstract
Introduction
There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies.
Methods
We assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017.
Citation impact
540
total citations
- FWCI
- 44.02
- Percentile
- 100%
- References
- 47
Citations per year
Authors
7- JLJeffrey L. CummingsCorresponding
Cleveland Clinic, University of Nevada, Las Vegas, Lou Ruvo Brain Institute
- GLGaram Lee
Cleveland Clinic, Lou Ruvo Brain Institute, Cleveland Clinic Lerner College of Medicine
- TMTravis Mortsdorf
Cleveland Clinic Lerner College of Medicine, Touro University Nevada
- ARAaron Ritter
Cleveland Clinic, University of Nevada, Las Vegas, Lou Ruvo Brain Institute
- KZKate Zhong
University of Nevada, Las Vegas, Global Alzheimer's Platform Foundation
Topics & keywords
Topics
Keywords
- Drug development
- Medicine
- Clinical trial
- Dementia
- Biomarker
- Disease
- Drug
- Oncology
No related works found for this paper.
Funding
- NINational Institute on AgingAward: R01AG084250 R56AG074001 U01AG073323 R01AG066707 R01AG076448 R01AG082118 RF1AG082211 R21AG083003 R35AG71476
- NINational Institute of General Medical SciencesAwards: NIA R25AG083721, P20GM109025, NIA R35AG71476
- NINational Institute of Neurological Disorders and StrokeAward: RF1NS133812